Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
PluvictoⓇ uptake reflects strong benefit/risk profile and
unmet need in post-taxane mCRPC
GROWTH
Sales evolution
Global sales, USD m
80
179
211
10
2
Q1
Q2
Q3
Q4
2022
Q1
2023
Q1 sales USD 211 million (mostly US)
Q2 sales expected broadly in line with Q1
200 unique accounts in US currently treating with PluvictoⓇ
PSMAfore pre-taxane study (which met its primary endpoint.
of rPFS) expected to be presented in H2 2023
FDA submission for PSMAfore including OS data is
planned for H2 2023 as aligned with FDA
Millburn facility approved to support US launch; Zaragoza
approved for EU
mCRPC metastatic castration-resistant prostate cancer. rPFS radiographic progression free survival.
18 Investor Relations | Q1 2023 Results
OS overall survival.
P
PLUVICTO™
NOVARTIS | Reimagining MedicineView entire presentation